HomeALKS • NASDAQ
Alkermes Plc
$27.07
After Hours:
$27.11
(0.15%)+0.040
Closed: Mar 28, 4:45:50 PM GMT-4 · USD · NASDAQ · Disclaimer
StockUS listed security
Previous close
$27.25
Day range
$26.91 - $27.33
Year range
$22.01 - $33.71
Market cap
4.52B USD
Avg Volume
2.33M
P/E ratio
8.85
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
(USD)Dec 2023Y/Y change
Revenue
377.48M
Operating expense
252.72M
Net income
112.78M
Net profit margin
29.88
Earnings per share
0.2257.14%
EBITDA
73.29M
Effective tax rate
-175.31%
Total assets
Total liabilities
(USD)Dec 2023Y/Y change
Cash and short-term investments
773.49M27.12%
Total assets
2.14B8.77%
Total liabilities
933.54M1.45%
Total equity
1.20B
Shares outstanding
167.08M
Price to book
3.78
Return on assets
6.19%
Return on capital
8.24%
Net change in cash
(USD)Dec 2023Y/Y change
Net income
112.78M
Cash from operations
Cash from investing
Cash from financing
Net change in cash
Free cash flow
About
Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies, the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and manufacturing facilities in Athlone, Ireland, and Wilmington, Ohio. Wikipedia
Founded
1987
Employees
2,100
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu